Literature DB >> 34808659

Atypical Case of POEMS Presented as Demyelinating Polyneuropathy With Motor Conduction Block.

Stacey Y Guo1, Alexandra O Duffy2, Ricardo A Maselli2, Ge Xiong2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34808659      PMCID: PMC8601671          DOI: 10.1097/CND.0000000000000385

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


× No keyword cloud information.
Polyradiculoneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) is a rare paraneoplastic syndrome due to an underlying plasma cell disorder. We present the case of a 62-year-old previously healthy man with acute onset ascending paresthesia and weakness after fever, chills, and fatigue for 1 week in March 2020. Guillain–Barre syndrome was suspected initially, and 5 days of intravenous immunoglobulin was empirically provided. His symptoms rapidly progressed, and he had to use a cane to walk. He was evaluated in our hospital in July 2020 after 15 lb weight loss. Physical examination was notable for edema in distal extremities and acrocyanosis in toes. Neurological examination revealed distal muscle atrophy and asymmetric moderate to severe weakness in bilateral distal extremities. Deep tendon reflexes were normal in upper extremities and absent in ankles. Sensation to light touch and pinprick was reduced with glove-stocking distribution in extremities. A nerve conduction study demonstrated asymmetric demyelinating polyneuropathy with multifocal motor conduction block (Fig. 1). The patient received empirica1lly plasmapheresis. The laboratory results showed mild thrombocytosis, elevated thyroid stimulating hormone and follicle stimulating hormone, but normal free thyroxine. An autoimmune workup was negative apart from elevated rheumatoid factor, erythrocyte sedimentation rate, and C reactive protein. Serum immunofixation studies revealed IgG lambda monoclonal band. Bone marrow biopsy demonstrated monoclonal lambda restricted plasma cells. A vascular endothelial growth factor (VEGF) was normal initially but elevated after plasmapheresis was held (Fig. 2). Although our patient did not have Castleman disease or sclerotic bone lesions based on his computed tomography and positron emission tomography scans, he met the current Dispenzieri diagnostic criteria for POEMS syndrome.[1,2] After the diagnosis of POEMS was made, our patient was started on dexamethasone, cyclophosphamide, and lenalidomide. His edema and weakness improved after chemotherapy. The VEGF level trended down and light chain normalized.
FIGURE 1.

Examples of motor conduction block in the right median and ulnar nerves. A, Conduction study in the right median nerve showing normal compound muscle action potential (CMAP) amplitude with stimulation at the wrist, but a severe reduction of CMAP amplitude with stimulation at the elbow, and further reduction of CMAP amplitude with proximal stimulation at the axilla. B, Conduction study of the right ulnar nerve showing similar findings as in the median nerve, except for reduction of CMAP amplitude with distal stimulation at the wrist. Note the absence of significant temporal dispersion of CMAPs with proximal nerve stimulations. F waves were absent in both nerves.

FIGURE 2.

VEGF level correlated with disease activity. Patient's VEGF level was 46 initially, which then increased to 105 before obtaining plasma exchange therapy on 8/1. After plasma exchange, patient's VEGF level decreased to 57 on 8/4. Plasmapheresis was discontinued, and patient's serum VEGF level rose to a high on 220. Finally, he was initiated on chemotherapy, cyclophosphamide, and dexamethasone, which resulted in further drop in the VEGF level to 82 on 9/7.

Examples of motor conduction block in the right median and ulnar nerves. A, Conduction study in the right median nerve showing normal compound muscle action potential (CMAP) amplitude with stimulation at the wrist, but a severe reduction of CMAP amplitude with stimulation at the elbow, and further reduction of CMAP amplitude with proximal stimulation at the axilla. B, Conduction study of the right ulnar nerve showing similar findings as in the median nerve, except for reduction of CMAP amplitude with distal stimulation at the wrist. Note the absence of significant temporal dispersion of CMAPs with proximal nerve stimulations. F waves were absent in both nerves. VEGF level correlated with disease activity. Patient's VEGF level was 46 initially, which then increased to 105 before obtaining plasma exchange therapy on 8/1. After plasma exchange, patient's VEGF level decreased to 57 on 8/4. Plasmapheresis was discontinued, and patient's serum VEGF level rose to a high on 220. Finally, he was initiated on chemotherapy, cyclophosphamide, and dexamethasone, which resulted in further drop in the VEGF level to 82 on 9/7. The diagnosis of POEMS syndrome requires the presence of both mandatory criteria (polyneuropathy and a monoclonal plasma cell proliferative disorder) and at least one major (sclerotic bone lesions, Castleman disease, and elevated VEGF) and one minor criterion (organomegaly, edema, endocrinopathy, skin changes, papilledema, and thrombocytosis/polycythemia). The plasma cell disorder underlying POEMS syndrome is typically Immunoglobulin A or Immunoglobulin G lambda restricted.[1,2] Osteoclastic bone lesions based on computed tomography and positron emission tomograph imaging are a characteristic of POEMS, which can have mixed sclerotic–lytic bone lesions, and referred to as osteosclerotic myeloma.[1] Neuropathy is a common initial presentation and is generally a rapidly progressive distal symmetric sensorimotor polyneuropathy with a feature of allodynia/hyperpathia. EMG/nerve conduction study typically demonstrated length-dependent sensorimotor polyneuropathy, diffuse demyelinating pattern with axonal loss. Conduction block is very rare in POEMS syndrome.[3] The hallmark of POEMS—multiorgan involvement—helps to differentiate it from other inflammatory or paraproteinemia-related polyneuropathy. Treatment of POEMS focuses on localized radiotherapy for those with localized disease, particularly, targeted to discrete bone lesions, or systemic treatment including autologous stem cell transplant or chemotherapy to patients with diffuse disease defined as either >3 bone lesions or clonal plasma cells.[3]
  3 in total

1.  Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP.

Authors:  Michelle L Mauermann; Eric J Sorenson; Angela Dispenzieri; Jay Mandrekar; Guillermo A Suarez; Peter J Dyck; P James B Dyck
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-03-06       Impact factor: 10.154

2.  POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.

Authors:  Angela Dispenzieri
Journal:  Am J Hematol       Date:  2019-05-23       Impact factor: 10.047

Review 3.  POEMS syndrome: clinical update.

Authors:  Rachel Brown; Lionel Ginsberg
Journal:  J Neurol       Date:  2018-11-29       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.